Santen Pharmaceutical Co., Ltd. (SNPHY)
OTCMKTS · Delayed Price · Currency is USD
11.22
-0.07 (-0.62%)
Feb 11, 2026, 10:24 AM EST
Santen Pharmaceutical Revenue
Santen Pharmaceutical had revenue of 72.88B JPY in the quarter ending December 31, 2025, a decrease of -4.56%. This brings the company's revenue in the last twelve months to 287.99B, down -4.61% year-over-year. In the fiscal year ending March 31, 2025, Santen Pharmaceutical had annual revenue of 300.00B, down -0.65%.
Revenue (ttm)
287.99B JPY
Revenue Growth
-4.61%
P/S Ratio
1.96
Revenue / Employee
74.82M JPY
Employees
3,849
Market Cap
3.60B USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 300.00B | -1.96B | -0.65% |
| Mar 31, 2024 | 301.97B | 22.93B | 8.22% |
| Mar 31, 2023 | 279.04B | 12.78B | 4.80% |
| Mar 31, 2022 | 266.26B | 16.65B | 6.67% |
| Mar 31, 2021 | 249.61B | 8.05B | 3.33% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Glass House Brands | 196.17M |
| Elite Pharmaceuticals | 122.89M |
| Silence Therapeutics | 25.83M |
| OpGen | 9.00M |
| Stem Cell Authority | 3.33M |
| Tian'an Technology Group | 2.12M |
Santen Pharmaceutical News
- 6 days ago - Santen Pharmaceutical Co., Ltd. GAAP EPS of ¥66.05, revenue of ¥210.76B - Seeking Alpha
- 7 weeks ago - Santen Pharmaceutical Launches Verkazia In China For Severe Childhood VKC Treatment - Nasdaq
- 3 months ago - Santen Pharmaceutical reports Q2 results - Seeking Alpha
- 9 months ago - Santen Pharmaceutical Co., Ltd. reports Q4 results - Seeking Alpha
- 3 years ago - Santen Pharmaceutical Co., Ltd. (SNPHY) Management on Q1 2022 Results - Earnings Call Transcript - Seeking Alpha